General Proximity emerged from stealth in Jan 2025, unveiling its proprietary OmniTAC platform designed to develop next generation induced proximity medicines. The company has raised $16 million to accelerate the development of treatments targeting undruggable proteins associated with cancer, cardiometabolic disease, neurodegeneration, and longevity.